Abstract:Background: There is mounting evidence to suggest that stromal cells play an integral role in the progression of prostate cancer (PCa). One of the most frequently altered growth factors in PCa is fibroblast growth factor-2 (FGF-2). It has previously been proposed that early stages of PCa are characterized by a primarily exogenous, that is, stromal cell-derived FGF-2 production, whereas advanced tumors rely more on an autocrine FGF-2 production. Prostate cancer progression is characterized by an increase of genomic instability including aneuploidy and structural chromosomal alterations. Herein, we address 2 problems that have not been comprehensively answered. First, we ask whether exogenous FGF-2 can directly drive genomic instability to promote PCa progression. Second, we investigate whether and to what extent stromal FGF-2 expression is maintained in advanced PCa and whether this influences tumor progression and patient prognosis. Methods: In vitro experiments to investigate the role of FGF-2 in numerical and structural chromosomal instability were performed using immunofluorescence microscopy, fluorescence in situ hybridization and single cell electrophoresis. A human patient-derived xenograft mouse model recapitulating osteoblastic PCa bone metastasis was used for in vivo validation experiments. The prognostic role of stromal FGF-2 expression was analyzed using immunohistochemical staining of a tissue microarray with primary tumor specimens from 162 predominantly high-risk patients with PCa. Results: Our results show that FGF-2 not only rapidly induces mitotic defects and numerical chromosomal imbalances but also an enhanced DNA breakage to promote chromosomal instability. Using the patient-derived xenograft model, we show that a deregulation of the FGF axis results in an increase of mitotic aberrations as well as DNA damage checkpoint activation in vivo. The FGFR inhibitor dovitinib was found to reduce numerical chromosomal instability as well as DNA breakage, thus underscoring the relevance of the FGF axis in promoting genomic instability. An overexpression of tumor cell-associated FGF-2 was detected in 52 of 162 patients (32.1%), whereas a stromal overexpression was found in 27 of 165 patients (16%). Remarkably, a strong stromal FGF-2 expression was associated with a significantly higher clinical stage and higher biochemical recurrence rate. Patients with strong stromal FGF-2 expression also had a significantly worse biochemical recurrence-free survival. Conclusions: Our results underscore that exogenous FGF-2 can shape PCa cell genomes and that stromal FGF-2 expression is detectable in a sizeable proportion of advanced PCa where it is associated with adverse clinico-pathological features. Our results highlight the impact of the tumor stroma on malignant progression and provide a rationale for a further exploration of components of the tumor stroma as therapeutic targets in PCa.

Basic Fibroblast Growth Factor Levels in Cancer Cells and in Sera of Patients Suffering from Proliferative Disorders of the Prostate

Expression of Basic Fibroblast Growth Factor(bfgf)in Prostatic Carcinoma Tissues

[Expression and Its Significance of B-Fgf in Human Benign Prostatic Hyperplasia and Prostatic Carcinoma Tissues].

Clinical Significance of Plasma Fibrinogen Level in Patients with Prostate Cancer.

Expression of Basic Fibroblast Growth Factor in Supratentorial Astrocytic Tumors and Its Implication

Clinical Significance of Presence of Serum and Urinary Basic Fibroblast Growth Factor in Diagnosis of Bladder Cancer

Acidic and basic fibroblast growth factor expression levels in cervical cancer and their effects on tumor cell proliferation

Expression of bFGF in malignant tumor and its clinical pathological sig-nificance

THE EXPRESSION OF BASIC FIBROBLAST GROWTH FACTOR (bFGF) AND ITS SIGNIFICATION IN TUMOR CELLS

Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate

The concentration of serum bFGF of patients with gastric cancer and its clinical significance

The FGF/FGFR system in the physiopathology of the prostate gland

[The Effect of Basic Fibroblast Growth Factor in Ovarian Cancer Growth and Angiogenesis].

Correlation of pituitary tumor transforming gene and basic fibroblast growth factor expression in prostate cancer and its clinicopathological features

Expressions of Basic Fibroblast Growth Factor(bFGF) in Ovarian Serous Neoplasms

EGR1 Promotes Proliferation in Prostatic Hyperplasia Epithelial BPH-1 Cells

Effects of modulation of basic fibroblast growth factor on tumor growth in vivo

EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND BASIC FIBROBLAST GROWTH FACTOR IN HUMAN NON-SMALL CELL LUNG CANCER AND THEIR CLINICAL SIGNIFICANCE

Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value

Hepatocyte Growth Factor Up-Regulates the Expression of the Bone Morphogenetic Protein (BMP) Receptors, BMPR-IB and BMPR-II, in Human Prostate Cancer Cells.

FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer